News | November 14, 2024
AstraZeneca Pharma India posts Q2 PAT at Rs. 38.43 Cr
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
Construction of the plant will commence in 2025 with first production expected to be in 2027
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
Strengthening focus in Alzheimer's disease and neuroscience pipeline
This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Union Government will provide a health cover of Rs. 5 lakh to any elderly person above 70 years of age
Product basket comprises 2,047 medicines and 300 surgical devices covering all major therapeutic groups
Subscribe To Our Newsletter & Stay Updated
